“‘word of mouth’ negativity among psychiatrists”- about Seroxat when it was first Licensed- says Psychiatrist…


Interesting take on the Seroxat debacle from (psychiatrist) Dr Neil Mcfarlane


 

“….As a psychiatrist, my perspective on Seroxat is that despite much having been written about it, there may be more to productively explore about how it was introduced in the UK. My own recollection is that there was a good deal of ‘word of mouth’ negativity among psychiatrists, many of whom felt it was being aggressively marketed to GPs, in a way which covered up both the poor side effect profile (compared with other SSRIs) and the dubiousness of its licence for ‘Social Anxiety Disorder’. There was also some talk of discontinuation problems.

That was years before the first ‘Secrets of Seroxat’ programme. I never had a patient ask to try it, as happened with other antidepressants (especially Prozac in the mid-1990s).”

https://drnmblog.wordpress.com/2019/04/27/seroxat-on-trial-again-in-2019/


 

 

The Level Of Patronization From Prof Carmine Pariante Is Off The Chart…


D5Erq9eWsAEcJgt

 

Difference-Between-Condescending-and-Patronizing-2hoity-toitiness

Just also to note (thanks to aunty psychiatry for the image): Carmine Pariante gets research funding from the drugs industry, and like every other Pharma-Whore in the world, they are paid to have a pro-drug view, and their pro-drug views suit their sponsors.

It’s a business arrangement, and psychiatric drugs are BIG business….

I think I ruptured my bowels from laughing so much at Carmine Pariante’s absolute nonsense interview about anti-depressants with Angela Rippon. It was like an episode of Blue Peter from the late 80s, with a doctor knows best slant….

 

I’ll let Bob Fiddaman explain….

 


https://fiddaman.blogspot.com/2019/04/pariantes-dish-of-day.html

 

Thursday, April 25, 2019

Pariante’s Dish of the Day

Image courtesy of @AuntyPsychiatry

Knock! Knock!
Who’s there?
Dishes.
Dishes who?
Dishes psychobabble at its finest.

Psychiatrist Carmine Pariante is a key opinion leader who often speaks on behalf of the Royal College of Psychiatrists (RCP), the coven that continually promotes bizarre brain disorders and the brain pellets whilst downplaying the adverse effects these toxins cause, to include horrific withdrawal problems and iatrogenic deaths.

Yesterday Pariante caused a Twitter storm when promoting his appearance on BBC’s “Truth or Scare,” hosted by former newsreader and British icon, Angela Rippon.

The bizarre rantings of Pariante had me perplexed. I’m going to try to dissect his comments for you but, frankly, I may need help from readers given I can’t understand how anyone can make such outlandish and unproven claims. Watching the show I couldn’t help but think of the Brothers Grimm fairy tales.

I interviewed Pariante myself months ago, an interview that came to an abrupt end because it seemed we couldn’t adequately address the first and most important issue. (See here)

The BBC show, Truth Or Scare, sets out to prove whether stories in the media are true versions of facts or if merely scary stories.

Pariante was batting for the side of the pill-pushers. It seems he was batting alone as there was no invite, to my knowledge, of any batter from the other side of the issue, one who could rebut Pariante’s televised claims. It seems the BBC may want only one opinion regarding brain pellets and depression.

BBC host, Rippon, took everything Pariante said at face value and never once asked for evidence. (More on this later.) She kicked off the show by asking Pariante to explain depression in laypersons terms. Here’s where the fun starts so hold on to your sides, folks, as they just might split!

“Brain cells are close but they are not physically connected so to communicate they need a chemical to go from one cell to another”, claimed Pariante, adding, “People with depression need a stronger connection.”

Pariante then showed Rippon an explanation of this by, um, well, by knocking on doors in a corridor. (See video below** where he appears around the 3 minutes, 12-second mark.)

Rippon then tells viewers, “For a more scientific explanation of how antidepressants work, Professor Pariante has recreated the effects of antidepressants in a culture lab.” She adds, “His team chemically induce brain cells in test tubes to mirror the state of depression. Antidepressant medication is then added.”

Pariante, speaking with Rippon, says, “If you induce depression in a dish, as you can see, new brain cells stop growing and you have much fewer cells compared to healthy conditions.”

Pariante then claims that once an antidepressant is added the number of new brain cells “rises again”.

I was just digesting the “depression in a dish” claim when Rippon claimed, “The Science certainly seems clear.”

At this point, I had to dry my eyes and change my underpants. Biting the table leg didn’t help with my state of uncontrollable laughter either.

Pariante later backs up his “Depression in a dish” claims by quoting the Cipriani study (back story here) – Pariante claims that Cipriani’s study “clearly shows antidepressants improve the symptoms of depression.”

When asked about the ‘dark side’ of antidepressants, Pariante said, “Antidepressants are no more or no less than any other medication, they are effective in most people, they are tolerated in most people, and in some people there are side effects, in a very small number of people there are severe side effects, but that’s like all medication.”

When asked about the dependency on antidepressants Pariante says, “There is no evidence that we are over prescribing antidepressants, yes more antidepressants are prescribed today than 10 years ago but, in fact, most people who need antidepressants are not receiving an antidepressant.”

Yes, he really did say this, and he also neglected to share that a recent study found nearly 56% of people taking brain pellets suffer withdrawal effects and 1.8 million people are currently at risk of severe symptoms when they decide to come off these drugs. (1) If Pariante gets his wish, these figures will, no doubt, rise.

The show (skit) also features two former patients who have opinions about brain pellets. It’s well worth watching if only to see the performance of Pariante and some of his bizarre claims and also how Angela Rippon seems almost smitten with him.

“The science certainly seems clear” wins a gold star for the BBC’s most unscientific quote of the year. Rippon’s quote was based on walking around a lab with a guy in a white coat knocking on doors and examining slides of depression produced in Petri dishes.

Approximately two hours after the show was aired on BBC, Pariante, rather bizarrely tweeted the following:

He really does himself no favours.

Here’s the video.

** The video was downloaded directly from the Stress, Psychiatry and Immunology Lab – SPI Lab Facebook page. Any copyright issues should be taken up with the owner of this page, ironically, Carmine Pariante.

If you can’t get the video to work, try here.

Bob Fiddaman

(1) Millions are warned over ‘severe’ side-effects while coming off anti-depressants with 56% of patients suffering withdrawal effects

 

 

GSK and ‘Future Wrongdoing’…


“….Whilst these originate in a different era for the company, they cannot and will not be ignored,” Sir Andrew said. “On behalf of GSK, I want to express our regret and reiterate that we have learnt from the mistakes that were made….”


“….The 100 top managers in the US business and the executive board will have to set aside a portion of their annual pay for three years in case they are found to be complicit in future wrongdoing, and the company will be able to claw back up to three times their annual bonus and long-term incentive pay…..

https://www.independent.co.uk/news/business/news/glaxosmithkline-pays-3bn-for-illegally-marketing-depression-drug-7904555.html

Interesting section of this article (brought to my attention by Sarah Price-Hancock- Thanks Sarah).

When GSK were fined 3 Billion for their various unethical shenanigans in 2012, one of the stipulations seems to imply that up to 100 of the top executives and managers would be liable to pay for any ‘future wrong-doing’.

Isn’t that incredible? as part of their corporate integrity agreement with the US dept of Justice they actually had to put in a part about ‘future wrong-doing’, as if they expected GSK to carry on committing fraud and unscrupulous business practices.

In 2014, GSK were then caught operating a massive bribery operation in China, and they were fined there too (half a billion US dollars).

It seems that this ‘future wrong-doing clause’ was a prophecy, because GSK did plenty more wrong-doing, however it seems the corporate integrity agreement wasn’t worth the paper it was written on…

Let’s hope the SEC, and the department of Justice in the US, have more bite than the utterly toothless sham-joke SFO in the UK.


 

The company pleaded guilty to criminal charges related to the marketing of Paxil for use by children between 1999 and 2003, when it:

* failed to reveal the existence of two scientific studies that showed the drug was ineffective in treating childhood depression;

* cut out important caveats to the conclusion of a third study which suggested it may improve a small number of symptoms in children;

* over-hyped the conclusions of that study, after it was published, in marketing materials at conferences and distributed to doctors.

GSK also illegally promoted Wellbutrin, another antidepressant, for the treatment of adult impotence, obesity and attention deficit, according to its guilty plea yesterday.

 

“….Sara Carlin, 18, was a talented student who dreamt of becoming a doctor, only for her to take her own life back in 2007, a little over a year after being prescribed anti-depressants. She was found hanging in the basement of her family home in Oakville, Canada.

The country’s health authorities put out warnings in 2003 and 2004 that prescribing newer antidepressants such as Paxil to teenagers could lead to behavioural changes and self-harm, but Sara brushed off her mother’s attempts to warn her off such drugs, saying her doctor had said they would lift her mood.

Colin Whitfield, 56, died just two weeks after he began taking the antidepressant drug Seroxat. The retired Welsh teacher was found in the garden shed of the family home having slit his own wrists in 2002.

At the inquest the coroner said that he had “grave concerns that this is a dangerous drug that should be withdrawn until detailed national studies are undertaken.”

Kathryn, Colin’s wife of more than 30 years, said that she had noticed a profound change in her husband’s behaviour once he started taking Seroxat, and the drug may have contributed to his unexpected suicide. “It didn’t fit the picture of who he was and we have no doubt that it was the drug that caused him to do it. He was a very caring, very protective father,” she said….”

Department of Justice and SEC Investigations Into GSK Still Ongoing Despite UK Serious Fraud Office Dubioulsy Dropping GSK Fraud Case..


After spending £7.5 Million on a 5 year investigation into GSK, the serious fraud office decided to drop the case (see here). I wasn’t surprised at this, because GSK are one of the most powerful UK companies. They are the Pharma cash cow in the UK, and the powers that be in England were never going to let a little thing like international mass fraud, bribery schemes, corruption and damage to consumers of GSK meds, get in the way of GSK’s (and thus- the UK’s) lucrative profits were they?

Of course not..

However, despite the UK’s thoroughly cowardly approach to GSK’s consistent bad behavior, it seems that the Department of Justice and the SEC in the US are continuing their investigations- presumably based on some of the info gleaned from the UK’s expensive SFO investigation.

Whether any of the information from this SFO investigation will ever see the light of day, is another matter. Furthermore, whether the Department of Justice or the SEC will take any disciplinary action against GSK, in light of all this, also remains to be seen.

I won’t hold my breath.

Anyhow, See Page 92/93 of GSK’s annual report for more on this..


https://www.gsk.com/media/5344/financial-statements.pdf

DOJ.png

 

 

Glaxo’s Abhorrent Involvement In The Irish Baby Home Controversy Is An Ongoing Scandal …


“….Up to 1,000 dead babies and children up to the age of 15 were sent to medical schools by nuns and religious institutions up to the 1970s.

The latest shocking revelation emerged this morning in the fifth interim report from the Mother and Baby Homes commission….”

 

https://www.irishmirror.ie/news/irish-news/mother-and-baby-homes-commission-14385210?fbclid=IwAR04LSYKhKHFz0Mb0StVlOvq9q5Y48UAcc-luZZDO1mGHijNzP0Tzw39AtM


 

For full story on Glaxo’s involvement in the Irish baby home experiment scandal see the link here-

 

https://www.irishexaminer.com/breakingnews/views/analysis/focus-of-mother-and-baby-homes-investigation-has-moved-onto-headline-generating-institutions-918332.html

 

“….In 2017, the Irish Examiner revealed that a previously unknown trial of lactose and baby formula was carried out using infants in Bessborough Mother and Baby Home by Glaxo Laboratories in the mid-1970s.

The extend of vaccine trials on children in care in Ireland by British pharmaceutical companies on children in care in Ireland has slowly been emerging through the media over the past 20 years.

These tests involved the trialling of various vaccine combinations by predecessor companies of pharmaceutical giant GlaxoSmithKline (GSK) — Glaxo Laboratories and Burroughs Wellcome.

These revelations generated more questions than answers — answers it is hoped the Mother and Baby Homes Commission can provide.

However, the fact that Glaxo Laboratories was also trialling other products on children here — namely lactose and baby formulas – is a new discovery.

A trial sheet obtained by the Irish Examiner revealed that Glaxo Laboratories carried out a “clinical acceptability and safety trial” of “Golden Ostermilk and Lactose”, while a separate trial sheet reveals a trial of “overseas milk powders (by 0111)”.

The “clinician responsible” for the tests was Eithne Conlon — a local Cork GP who worked with Bessborough for many years.

The trial sheets recorded a range of reactions to the products. These included vomiting (slight, moderate, severe, or none), excessive regurgitation, wind (slight, moderate, severe, or none), stools (locae, normal, or constipated) and stool colour (yellow, grass green, olive green, yellow green, no stools, meconium, changing).

Other “abnormal conditions” were also noted. These included excessive crying, irritability, napkin rash, thrush, and others.

The latter trial sheet was contained in the records of Breda Bonass, who had sought information on her medical history from Tusla under Freedom of Information.

The former only came to light when Ms Bonass sought further information from Tusla.

However, the trial sheet for “Golden Ostermilk and Lactose” was also found in the antenatal records of other women — and all contain identical details including patient numbers — something which the FOI officer told Ms Bonass was “perplexing”.

Ms Bonass asked the Sisters of the Sacred Hearts of Jesus and Mary and GSK for an explanation.

The nuns responded via their solicitors, telling her they no longer held the records nor had any access to them and that she should go to Tusla.

GSK’s UK data protection section informed her that the data had been “destroyed” as the “retention period has already expired some years ago”.

It told this newspaper it was “unable to locate any records relating to a 1974 study” but that it had located records relating to a trial from 1967.

The assumption, therefore, would be that the 1974 study’s purpose was to compare current milk powder with a newer formulation.

“The records contain no names or information about the children involved,” said GSK in a statement.

With regard to the consent of mothers, GSK said that, due to the fact that it had no records, it could not confirm who gave consent but that its assumption was that it would have been “those Sisters running the homes as the legal guardians”. Obtaining consent would been left to the doctor conducting the trial.

GSK said the identical sheets were probably blank forms or templates and that the information entered “appear to be codes, possibly relating to a spreadsheet collating all responses”.

It also confirmed that this was the first time it was made aware of this study and that it had not been asked to disclose it in any official capacity, “as this is clearly outside of the current Commission’s [Into Mother and Baby Homes] vaccines inquiry”.

The Commission is only tasked with examining vaccine trials carried out by GSK legacy companies, not other forms of product testing that may have occurred.

The inquiry has now been delayed until February 2020. The delays have caused anger to many of the survivors representative groups desperate for answers and justice. The above revelations relate to just one of the homes under its remit. It is looking at many more and, undoubtedly, has access to hundreds of thousands more records.

The issue of Mother and Baby Homes, forced and illegal adoptions, infant deaths and the myriad of practices surrounding the confinement of thousands of women in Ireland are often spoken about as part of Ireland’s past. They are not. The fact we still don’t fully grasp the enormity of what happened shows this is a story with contemporary relevance.

The more you investigate these matters, it is often more questions that emerge – not answers. The Commission has another 12 months to find them.

Scandalous Waste Of Time And Money…


It will be interesting to see what more of these freedom of information requests about the SFO’s bogus sham investigation in GSK reveal..

 

https://www.thetimes.co.uk/article/dropped-glaxosmithkline-inquiry-cost-serious-fraud-office-7-5m-2t5bmtpv5

The Serious Fraud Office spent £7.5 million on its corruption investigation into Glaxosmithkline before dropping the high-profile case.

It abandoned the five-year inquiry into alleged bribery at the FTSE 100 pharmaceuticals group in February after Lisa Osofsky, its new boss, reviewed the agency’s caseload.

The criminal investigation had been among the SFO’s longest-running and involved one of Britain’s biggest companies. Glaxo is valued at £76 billion and was formed through the merger in 2000 of Glaxo Wellcome and Smithkline Beecham.

The costs of the inquiry have been disclosed after a freedom of information request.

Is This A Late April Fools Joke Or What?…


http://www.jobfixture.com/archives/230410/ethics-compliance-officer-at-glaxosmithkline-gsk/?utm_source=feedburner&utm_medium=twitter&utm_campaign=Feed%3A+No1GlobalCareerPortal+%28+No+1+Global+Career+Portal%29

Ethics & Compliance Officer at GlaxoSmithKline (GSK)

/
/
GlaxoSmithKline (GSK), one of the world’s leading research based pharmaceutical and healthcare companies, is committed to improving the quality of human life by enabling people to do more, feel better and live longer. GSK employs over 97,000 employees in over 100 countries worldwide.GlaxoSmithKline Consumer Nigeria Plc is one of Africa’s largest consumer healthcare companies, producing leading brands such as Lucozade, Ribena and Panadol.

We are recruiting to fill the position below:

Job Title: Ethics & Compliance Officer

Requisition ID: WD205739
Location: Lagos

Position: Full time

Functional area: Governance, Ethics and Assurance

Job Purpose

  • Through the successful implementation of GSK Internal Control Framework and compliance programs, this role will support Global Ethics and Compliance (GEC) strategy to ensure that the right product gets to the right patient or consumer in the right way.
  • This role moreover supports GSK’s mission to help people do more, feel better and live longer.

Specifically, the Nigeria Country Ethics & Compliance Officer will:

  • Ensuring effective compliance oversight of the Nigerian Rx business, focusing on the Commercial business, but also bridging across other support functions including Regulatory, Quality, Medical, Supply Chain, Procurement, IT, Finance, etc., supporting the establishment of strong internal controls
  • Supporting the Nigeria General Manager of Rx to ensure compliant processes and solutions working with GEC and Business Unit leadership teams;
  • Promoting a value based compliance culture through engagement communication and training initiatives;
  • Supporting early and proactive identification and management of risks aligning with GSK’s Risk Management process

Key Responsibilities

  • Working with GSK Pharma senior leaders across designated departments to lead the implementation of a values-based compliance program in Nigeria and to promote a values-based culture in a way that supports GEC and Pharma strategies.
  • Partnering with Pharma senior business leaders to proactively identify, evaluate and manage risks, in accordance with Policy 500 and GSK internal control framework, in a way that enables sustainable business growth.
  • Advise the business on risks associated with emerging business strategies and provide pragmatic options for risk mitigation and management. Ensure that the Nigeria based business have an effective risk management strategy that aligns with GSK’s Risk Management methodology.
  • Ensuring adequate internal controls are in place across the Nigeria business by independently assessing efficiency of the internal control framework. Provide insight, best practice, guidance and assurance to build, test and validate the robustness of these business controls. Support delivery of clear and integrated compliance solutions.
  • Driving accountability throughout Nigeria to ensure greater business transparency, speak-up culture and reinforcing trust in GSK from customers, business partners, and patients.
  • In partnership with CIT (Corporate Investigation Team), HR and Legal ensuring that reported concerns are promptly and thoroughly investigated, with suitable corrective and remediation action and discipline when appropriate. Provide oversight on all investigations from his/her business.
  • In partnership with the business, ensuring adequate preparation for internal audits of significant compliance risks and delivery of prompt responses to audit findings.
  • Serve as the main contact and coordination point for independent business monitoring. Help to identify root cause issues to eliminate key risk areas
  • Act as the champion for GSK Values; driving our Values Assurance strategy into the depths of the organisation and increasing the values maturity of the organisation
  • Acting as a change leader for standardization where appropriate, to simplify the complexity of practices while maintaining adherence to GSK policy and Values.
  • Understanding the opportunity for business collaboration and new business models ensuring the risk management and controls framework is adequate.
  • Development of communication and training strategy of GEC and ad hoc implementation to fully embedding desired compliance culture within Nigeria.
  • Being the local expert on a wide range of compliance topics e.g. ABAC, TPO, Local Regulations and responsible for advising the Nigeria based staff on compliance with these areas
  • Engage with external parties to promote and defend GSK’s industry ethical lead and shape the external environment
  • As a key member of the PH and the Nigeria Country Executive Board, encourage discussion of relevant, significant risks and ensure that issues and conclusions are escalated upwards and consistently across the market
  • Participate in GEC initiatives/projects/working streams
  • Developing and implementing tools which empower employees to make ethical and legally compliant decisions. Provide compliance support to Nigeria based staff, as well as advisory and interpretation services in relation to GSK Policies and SOP as required.
  • Partner with other governance groups (e.g. HR, Finance, Medical, Legal) to develop integrated compliance solutions
  • Distill complex issues to create right-size, simple solutions to problems
  • Demonstrate learning agility and ability to learn new things quickly
  • Solid understanding of any relevant healthcare compliance standards in the market
  • Ability to influence leadership behaviours in line with GSK Values

Application of Knowledge:

  • Has a deep understanding of the BU’s products, competitors, industry issues and regulations.
  • Extensive knowledge and insight into global markets and underlying reasons for current conditions.
  • Understand how nuanced changes in strategy influence risk to GSK
  • Knowledge & experience with healthcare laws and requirements.
  • Knowledge & experience with compliance programs and processes
  • Ability to provide high degree of reliance and accountability to senior management
  • Strong advocacy skills and sound business judgment at senior levels
  • Organised and capable of working in an influencing role at all levels, particularly senior management levels
  • Excellent interpersonal skills to enable effective and influential internal and external contacts.
  • Experience dealing with government regulators and prosecutors
  • Possesses organisational knowledge required for identifying areas of compliance vulnerability and aligning the compliance functions with the business.
  • Knowledgeable of applicable government laws and regulations relating to the company.
  • Superior listening skills, analytical ability to diagnose problems, resolve conflict, and develop practical solutions.
  • Ability to manage sensitive confidential issues with complete discretion.
  • Demonstrated risk management, process improvement, and/or project management skills.
  • Maintain a high degree of credibility, independence, integrity, confidentiality and trust.
  • Exhibit strong analytical skills and an understanding of operational processes and technology concepts.
  • Strong writing skills required to write and edit policies and procedures, issue memoranda and compile program reports.
  • Exhibits excellent presentation skills with large and small audiences.
  • Good networker internally and externally to GSK

Problem Solving & Innovation:

  • A strong positive influence the culture of GEC and GSK to embrace GSK values decision making and effective risk management.
  • Viewed as a trusted team member by senior leaders and sought out for flexible thinking and strategic advice.
  • Establishing a culture and executing strategies which fundamentally raise the importance of customers in the organisation,
  • Champions project ideas.  Leads cross-organisation, complex projects. Supports development of new project managers.
  • Encourages and motivates peers and staff to give their best. Champions the development and success of the Compliance team. Create an environment that enables teams to perform at its best and builds trust and team spirit to enhance the effectiveness of the group.

Interaction:

  • Works with leadership teams to shape and define business strategies, working to manage the interface of agendas and drivers between other relevant areas of GSK. Helps the BU/Function evaluate multiple strategic alternatives.
  • Shares best practices with peers in the industry through informal discussions and presentations at educational events.

Impact:

  • Accountable for ensuring Nigeria compliance program is effective and fully implemented.
  • Accountable for implementation of compliance initiatives aligned with corporate initiatives e.g. following Strategic Review recommendations
  • Ensuring that GSK’s compliance culture is embedded at all levels of the organisation
  • Accountable for ensuring employees understand compliance requirements and use good judgment in activities and for ensuring appropriate monitoring and auditing to verify.
  • Manages policy and process enhancements and compliance issues and projects that apply to Nigeria and protect against significant liabilities.
  • Oversight of BU compliance champions, to ensure full deployment and coordination of corporate, Nigeria and BU risk management and compliance processes at all levels.
  • Establishes and maintains credibility and trust throughout the organisation and is able and willing to consistently advocate disciplinary actions for compliance and ethics violations.

Basic Qualifications

  • Degree in Business, Medical, Accounting, Engineering, Risk Management

Work Experience:

  • Minimum Level of Job-Related Experience required  5-10 year+ in Compliance/Audit/Legal/Internal Controls role
  • Prior experience is essential in facilitating judgment related decisions and implications of risk within a commercial business

Other Job-Related Skills/Background:

  • Good understanding of BU structures and processes.
  • Broad knowledge of GSK business and operating model
  • Expert level knowledge of Internal Control Framework and risk management principles and ability to translate theory into practice.
  • Good working knowledge of the GSK system of internal control, and its organisational elements.
  • Experience in audit, risk management, compliance and other governance fields desirable.
  • Ability to maintain confidentiality and trust around sensitive compliance issues.
  • Good degree of organisational awareness; demonstrated ability to develop solutions to complex problems and challenges.
  • Self-starter, results-oriented.
  • Ability to influence, coach and co-ordinate teams to initiate, plan, control and execute projects in smarter and more efficient ways, flexing the approach as needed for local context.
  • Familiarity with IT systems and technology, specifically Connect GSK, Teamsites, CDMS for storage and accessibility of policies
  • Teamwork – ability to work and contribute collaboratively as part of one team, respecting individual styles and cultural differences while focussed on delivery of the overall project objective.
  • Ability to work effectively and sensitively in a highly matrixed organisation across geographies and cultures.
  • Animation, facilitation and presentation skills
  • Detailed working knowledge of GSK Change Framework and Lean Sigma methodologies a plus
  • Enable and Drive Change: ability to define an approach that results in project stakeholders owning and sustain the change.
  • Flexible Thinking: Ability to flex and tailor standard approaches to fit the needs of the project and the local environment
  • Strong problem solving skills that are pragmatic, which demonstrates a strong understanding of the business.
  • Continuous Improvement: Determination and confidence to challenge the existing ways of working and shift current thinking to embrace working in a smarter, more efficient and simpler ways.
  • Relationship Building: Ability to build lasting, mutually beneficial win-win relationships with key project stakeholders and senior leaders
  • Strong interpersonal skills with excellent written and oral communication skills, including presentations to large and small audiences, with the ability to influence individuals at all levels of the organisation.
  • Demonstrated ability to work and influence others to work in accordance with company Values.

Application Closing Date
Not Specified.

How to Apply

Interested and qualified candidates should:
Click here to apply online